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Abstract
Background: In the literature, supplement of soy aglycons of isoflavone as estrogen agonists in
improvement of serum biochemical attributes, liver antioxidative capacities and vaginal epithelium
protection has been meagerly investigated. In this study, ovariectomized (OVX) rats were used as
an animal model to simulate post-menopausal status. Supplementary health benefits of soy aglycons
of isoflavone (SAI) on improvement of growth and serum biochemical attributes, enhancement of
liver antioxidation-related capacities and protection of vaginal epithelium of the OVX rats were
assessed.
Methods: As an in vivo study, 30 OVX Sprague-Dawley rats were distributed into OVX (positive
control), OVX/LSAI (low SAI group – supplemented with 0.0135% SAI being equivalent to 80 mg
per day for a 60 Kg-human), and OVX/HSAI (high SAI group – supplemented with 0.027% SAI) and
10 rats with sham operation as negative control fed with basal diet.
Results: The average daily gain (ADG), feed intake and feed/gain ratio were higher for the OVX
groups than the sham group (P < 0.05). Serum isoflavone concentrations of the OVX rats were
increased by SAI supplementation. In comparison, significantly lower serum cholesterol and LDL
(low-density lipoprotein) levels, and higher HDL (high-density lipoprotein) levels were detected for
the rats of OVX/HSAI group (P < 0.05). SAI supplementation also increased iron chelating ability
and decreased values of TBARS (thiobarbituric acid-reactive substance) (P < 0.05) of liver extracts.
Liver catalase activity and total antioxidative activity (trolox equivalency) were enhanced by HSAI
supplementation (P < 0.05). Decrease of vagina epithelial cellular linings of the OVX rats were
noticeably improved by dietary supplementation with SAI.
Conclusion: Diets supplemented with soy aglycons of isoflavone have conferred health benefits
to the OVX rats, in comparison to the sham rats fed with basal diet, by detection of higher serum
isoflavone concentrations, significantly lower contents of serum cholesterol and LDL, and higher
contents of serum HDL, increased iron chelating ability, lower contents of TBARS (thiobarbituric
acid-reactive substance) and enhanced catalase and total antioxidative (as trolox equivalency)
activities of the liver extracts, and protection of the epithelial cellular linings of vagina in the former
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Open Accessrather than in the latter. This evidences that estrogen-agonist chemoprevention of menopausal-
related cardiovascular diseases, decreased liver antioxidative capacities and epithelial degeneration
of vagina could be achieved by dietary supplementation with soy aglycons of isoflavone.
Background
Coronary heart disease, hyperlipidemia and osteoporosis
are common post-menopausal syndromes which are
closely related to deficiency of estrogen. HRT (hormone
replacement treatment) is one of the alternative treat-
ments in relief of post-menopausal symptoms. However,
thelikelytendencytoinduceuterusandbreastcancersdue
tosideeffectsofHRTisconcerned.Phytoestrogens,suchas
soyisoflavonesofestrogenagonists,haveweakestrogenic
activities. Soy isoflavones as alternatives of HRT to solve
post-menopausalproblemsandavoidthesideeffectshave
been demonstrated [1]. For food safety consideration,
McClain et al. [2] reported that genistein, orally admini-
strated with mice and rats up to 2000 mg/kg, was not
mutagenic or clastogenic. For Chinese and Japanese, their
dietary items contain large amounts of soybean products.
As estimated, they consume approximately 40–80 mg of
soybean isoflavones daily. In comparison, hyperlipide-
mia, coronary hearty disease and post-menopausal
syndromes for these Asians are markedly lower than the
Europeans and Americans who consume much lower
amounts of soybean products in their normal diets [3,4].
Soy isoflavones are most available and affordable source
of phytoestrogen in the world. Isoflavones are polyphe-
nols, featuring with 1–3h y d r o x y l(
-OH) groups. These
-OH groups are reactive, as is vitamin E, to attach free
radicals in production of stable radicals and performance
of antioxidants [5]. Soy isoflavones exhibit inhibitory
effects on lipid and LDL oxidation [6,7] and reduction of
atherosclerosis, coronary hearty disease and cancers
incidence [8]. Soy isoflavones also increase cholesterol
metabolic rate and reduce hyperlipidemia crisis [9].
Among the molecules of soy isoflavones, aglycon forms
of genistein and daidzein are absorbed faster by human
and in higher amounts than their glucosides [10].
Genisteinanddaidzeinexertmorepotentestrogenagonist
and antagonist activities than do other test molecules,
mainly depending on level of supplementation [8]. In the
literature, supplement of soy aglycon isoflavones to
render estrogenic functions on improvement of serum
biochemical attributes, antioxidative capacities and vagi-
nal epithelium protection has been meagerly studied. In
this study, ovariectomized rats were used as an animal
model to simulate post-menopausal status. Dietary
supplementation of aglycons of soy isoflavones in
affecting serum biochemical attributes, lipoprotein
profile, antioxidative capacities and histopathological
examination of the vaginal epithelium were investigated.
Methods
Ovariectomy of Sprague-Dawley rats
Ovariectomy was performed when the rats female were
sexually mature (ca. 11 week-old). The abdomen area of
each rat was sterilized with 75% ethanol solution and
opened by surgery. After the ovary was ligated and cut
out, the uterus and adipose tissue were put back and
sewn up. The sham rats were just subjected to opening of
the abdomen and then sewn up. Rats were recovered for
2 months prior to the experiment.
Animal treatment
Thirty ovariectomized Sprague-Dawley rats (average body
weight was 226.5 ± 5.6 g) were randomly distributed into 3
groups, namely, a positive control (OVX) and two groups
with dietary supplementation of soy aglycons of isoflavone
(SAI). Another group of 10 sham rats was assigned as
negative control. Rats of the positive and negative control
groupswerefed withbasal diet (Table 1). Twotreatments, i.
e.,alow supplementationgroup(OVX/LSAI,supplemented
with 0.0135% SAI) and a high supplementation group
(OVX/HSAI, supplemented with 0.027% SAI). The SAI
contains 4.5% daidzein, 14.5% genistein, ca. 1.0% of other
Table 1: Composition of the experimental diets for
Sprague-Dawley rats
Ingredients Content (%)
Casein 20.0
Sucrose 50.0
Cornstarch 15.0
Fiber 5.0
Corn oil 5.0
DL-methionine 0.3
AIN-Vitamin premix
a 1.0
AIN-Mineral premix
b 3.5
Choline bitartrate 0.2
Calculated value:
Crude protein, % 18.78
Metabolizable energy, kJ/g 14.85
Lysine, % 1.42
Methionine, % 0.49
Ca, % 0.85
P, % 0.67
aAIN vitamin mixture ingredient: Vitamin A, 22.01 IU/g; Vitamin D3, 4.5
IU/g; Vitamin E, 49.01 IU/g; Carotene, 4.5 ppm; Vitamin K, 0.5 ppm;
Thiamin, 17.2 ppm; Riboflavine, 8.0 ppm; Niacin, 123.7 ppm; Pantothenic
acid, 24.0 ppm; Folic acid, 5.9 ppm; Pyridoxine, 6.0 ppm; Biotin, 0.2 ppm;
B12, 22.0 mcg/kg.
bAIN mineral mixture ingredient: CaHPO4, 50%; NaCl, 7.4%;
K3C6O5O7.H2O, 22%; K2SO4, 5.2%; MgO, 2.4%; MnSO4, 0.35%; FeSO4,
0.6%; ZnO, 0.16%; CuSO4, 0.03%; KIO3, 0.001%; Na2SeO3.5H2O,
0.001%; CrK(SO4)2. 12H2O, 0.055%.
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Chiayi, Taiwan). The low supplementation level (LSAI) was
estimated by anequivalencyof80mgper daydestinedfora
60kghuman[11][(80mg/60kg)×6.25(aconversionfactor
of adult human to rat) = 8.33 mg/kg BW (dose for rats);
8.33mg/kg×0.3kg(BWofrats)=2.5mg/d;2.5mg/0.0185kg
(average daily feed intake) = 0.0135% (dietary level)]. The
required amounts of SAI were deposited and mixed into
basal diet. The rats were housed in individual cages and
raisedfor3months.Waterandfeedswerefreeaccess.Room
temperature and light/dark cycle was set at 25°C and 12 h,
respectively. Animals used in this experiment were cared for
under the guidelines stated in the Guide for the Care and Use
of Agricultural Animals in Agricultural Research and Teaching.
Body weights at initial and final stages and feed consump-
tionsweredetermined.Handlingandkillingoftheratswere
in full accordance with the Institutional Animal Care and
Use Committee (IACUC) guidelines for the care and
management of laboratory animals.
Serum, liver and vagina sampling and preparation
Rats were sacrificed after anesthesia by CO2.F r o me a c h
rat, 10 ml blood was sampled from the anterior artery.
Blood samples were centrifuged at 2000 g for 10 min to
obtain serum and stored at -20°C. Then, liver tissue
samples were taken and subjected to analyses.
For liver extract preparation, aliquots of liver tissue (ca.
5 g) were deposited into tubes with 10 ml of buffer
solution (0.25 M sucrose in 1 mM EDTA-2Na, pH 7.4),
pre-cooled in an ice bath, and homogenized (Ystral
GmbH, D-7801, Dottingen, Germany) for ca. 1 min. The
homogenized solution was centrifuged at 800 g,4 ° Cf o r
10 min to remove debris. The supernatant was further
centrifuged at 10,300 g, 4°C for 10 min and the upper
fraction was subjected to ultra-centrifuging at 105,000 g,
4°C for 60 min (Beckman L8, Beckman Instruments Inc.,
Bensenville, IL). The final supernatant (cytosol fraction)
was collected and stored at -80°C for determination of
antioxidative capacities.
Analyses of serum biochemical attributes
Serum estradiol concentrations were quantified by a
commercial ELISA kit (Active Co., Webster, TX). Choles-
terol level was analyzed by an enzyme kit and an
autoanalyzer (Roche. Cobas, Miras, Switzerland). Lipopro-
tein profiles were determined by electrophoresis and
intensity of the separated specific bands was quantitatively
scanned by a densitometer (Helena Co., Beaumont, TX).
Serum isoflavone levels were analyzed by HPLC and PID
equipped with a C18 column at 40°C with a column
oven. Detection wavelength and injection volume were
254 nm and 20 μl, respectively. The mobile phase
comprised 0.1% trifluoroacetic acid (A solution) and
acetonitrile (B solution). Each run was initiated with a
programmed mode with A solution at 1.5 ml/min for
2 5m i n ,i n c r e a s e dt o2 2 %Bs o l u t i o ni n1m i n ,f u r t h e r
increased to 25% B for 14 min, 50% B for 10 min, 80% B
f o r5m i na n df i n a l i z e dw i t h8 0 %Bs o l u t i o nf o r6 0m i n .
Authentic daidzein and genistein (Sigma Chem. Co., St.
Louis, MO) were run concurrently as standards and based
for estimation of total isoflavone concentrations. The
detection limit was 0.1 μg/ml.
Determinations of antioxidative capacities of liver
extracts
Superoxide dismutase (SOD) activity of liver extracts was
determined following the Ellerby and Bredesen [12]
method. Briefly, 15 μl of the stock 6-hydroxydopamine
was deposited into 1 ml of 0.05 M sodium phosphate
buffer solution containing 0.01 mM diethylenetriamine-
pentaacetic acid (pH 7.4) and 10 μl liver extract and
subjected to absorbance monitoring at 490 nm (Hitachi
U-2000, Tokyo, Japan) in quantification of 6-hydroxydo-
pamine auto-oxidation. One unit of enzyme activity was
expressed as mg of protein resulted in 50% inhibition of
6-hydroxydopamine auto-oxidation per min. The deter-
mination was conducted in triplicate and a commercial
SOD(SigmaChem.Co.)wasusedasastandardreference.
Catalase activity of liver extract was measured following
the method described by Ellerby and Bredesen [12].
Decomposition of 1.0 millimole of H2O2 per min was
definedasonecatalaseunit.Acommercialcatalase(Sigma
Chemical Co.) as a reference was run concurrently.
Enzyme activity was expressed as unit/mg protein.
Glutathione peroxidase (GSH-Px) activity of each liver
extract was determined following the method reported by
Bhat et al. [13]. For each determination, 0.8 ml of substrate
buffer solution containing 1 mM EDTA, 1 mM NaHCO3,
0.2 mM NADPH, 1 U/ml glutathione reductase, 1 mM
glutathione and 100 mM KH2PO4(pH 7.0)wasmixedwith
25μl of liverextract andincubatedat25°Cfor 5 min.Then,
0.1 ml of H2O2 (2.5 mM) was added to initiate catalysis for
3 min prior to absorbance determination at 340 nm
(Hitachi U-2000). One unit of activity was expressed as 1.0
nanomole of NADPH oxidized/mg protein/min.
Thiobarbituric acid-reactive substance (TBARS) in each
liver extract was determined according to the procedure
reported by Tarladgis et al. [14] and expressed by
nanomole MDA/ml. Peroxide value (POV) was deter-
mined following the procedure reported by Sebranek
[15]. Conjugated diene hydroperoxide contents were
measured according to the method described by Osawa
et al. [16]. Cellular protein concentration was determined
by Lowry et al. [17] method.
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extractwas determinedfollowing the procedurereported by
Erel[18].Briefly,200μl of reagent A (acetate buffersolution
containing 0.4 M CH3COONa and 0.4 M glacial acetic acid,
pH5.8)wasmixedwith20μlofreagentB(glacialaceticacid
buffer solution containing 30 mM CH3COONa, 30 mM
glacieraceticacid,and 2.86 M H2O2, pH 3.6). Then, 0.549 g
ABTS [2,2'-azinobis-(3-ethylbenzothiazoline-6-sulfonic
acid)] was dissolved in 100 ml of prepared solution. and
further mixed with 5 μl of liver extract. After incubation at
25°C for 5 min, absorbance at 660 nm was determined
(Hitachi U-2000). Authentic trolox (Sigma Chem. Co.) was
used as a reference for concentration estimation.
Iron chelating ability was determined according to the
method reported by Osawa et al. [16]. Briefly, in a quartz
cuvette containing 2.5 ml of 2 μM linoleic acid, 0.05 M
of Tris-HCl, 0.15 M of KCl and 0.5% of tween-20 (pH
7.4), 0.5 ml of 0.1 mM FeSO4 and 1.5 mM H2O2,1 0μl
of liver extract was added, mixed and incubated at 37°C.
At 0 h and 15 h of incubation, the conjugated diene
hydroperoxide (CDHP) concentrations were quantified
by absorbance determination at 234 nm. Iron chelating
ability was expressed by percentage of inhibition of
CDHP formation (chelating ability = sample ABS value/
control ABS value ×100).
Histopathological examination of vaginal epithelium
For specimen preparation, the vagina was dissected from
each sacrificed rat and subjected to fixation with 10%
buffered formalin for 48 h. Epithelial tissues were
processed by a tissue processor. Vagina sections (5 μm
thickness) were prepared and stained with hematoxylin-
eosin. The specimens were then subjected to histopatho-
logical examination and photographing. The epithelial
cellular linings were classified into two categories,
namely, 1–3a n d4 –6 layers, for characterization of
vaginal degeneration caused by ovariectomy.
Statistical analyses
Experimental data were analyzed by SAS (statistical
analysis system) for variance comparison among the test
groups. Tukey's test [19] was subjected to significance
analysis according to the following model,
YT P e iji j k =+ ++ m
Where Y is a dependent variable, μ represents mean, T is
the treatment effect, P is the pen effect and e is the
random residual error term. Data are expressed as mean
± SD with a significant difference level at P < 0.05.
Results and discussion
Effects of dietary supplementation with SAI on growth
p e r f o r m a n c eo ft h et e s tr a t sa r es h o w ni nT a b l e2 .T h e
average daily gains (ADG) and feed/gain ratios for the
ovariectomized (OVX) rats were higher than those of SAI-
supplemented rats (P < 0.05). Average daily feed intake
and energy expenditure for the OVX rats was increased,
mostlydue toovariectomy(P <0.05).Whencomparisons
were made among the SAI supplemented groups with the
sham group, an insignificant difference on growth
performance was observed (P <0 . 0 5 ) .T h i sw a si n
agreement with the observation that decrease of estrogen
of rats after ovariectomy may result in increase of body
weight [20]. Mook et al. [21] addressed that ovariectomy
stimulates feed intake of rats. Dietary supplement of
estrogen in the diet of rats may result in decrease of feed
intake and body weight gain [22].
Effects of diets supplemented with SAI on serum
biochemical attributes of the test rats are shown in
Table 3. Serum isoflavone concentrations of the SAI
supplemented groups were higher than those of the un-
supplemented (OVX) group (P < 0.05). The OVX group
had higher serum cholesterol contents than the sham
groups (P < 0.05). The lower serum cholesterol levels for
the OVX/HSAI group than the OVX groups were observed
(P < 0.01). However, the serum estradiol levels as affected
by SAI supplementation and ovariectomy differed insig-
nificantly among the test groups (P < 0.05). Even the SAI
supplemented groups had higher estradiol values than
the OVX group, the difference was not statistically
significant (Table 3).
Table 2: Effect of supplementation of soy aglycons of isoflavone on growth performance of Sprague-Dawley rats
Determinations Rats with different treatments
Items Sham OVX OVX/LSAI OVX/HSAI
Average daily gain (g) 0.56 ± 0.16
b 0.83 ± 0.23
a 0.83 ± 0.20
a 0.79 ± 0.21
a
Average daily feed intake (g) 13.74 ± 0.70
b 17.81 ± 0.98
a 18.34 ± 1.08
a 18. 43 ± 1.08
a
Energy expenditure (kJ/d) 204.0 ± 10.4
b 264.5 ± 14.6
a 272.4 ± 16.0
a 273.7 ± 16.0
a
Feed/Gain 26.28 ± 3.33
a 21.24 ± 1.70
b 22.07 ± 3.80
b 22.20 ± 3.46
b
a,bMeans (± SD, n = 10) in the same row with different superscripts differ significantly (P < 0.05). SAI: soy aglycons of isoflavone; Sham: negative
control; OVX: overiectomized rats as positive control; OVX/LSAI: overiectomized rats with low level of SAI supplementation; OVX/HSAI:
overiectomized rats with high level of SAI supplementation.
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activity. Their structures are similar to estrogen and
enabling binding competition to the estrogen receptors
[23,24]. The binding affinity to estrogen receptor of
genistein and daidzein is about 1/100 and 1/1000 of
estradiol and known as weak estrogens [25,26]. For
humans, Johnson et al. [27] and Messina and Loprinzi [1]
suggested that supplement of soy isoflavones for post-
menopausal women may reduce risk of incidence of
uterus endometrial cancer.
Serum isoflavone (daidzein + genistein) levels of rats for
the SAI supplemented groups were higher than those of the
sham group (Table 3). It is obvious that serum isoflavone
levels were increased by dietary SAI supplementation. This
was in agreement with Ishimi et al. [28] who found that
serum isoflavone concentrations of mice increase after
feeding mice with isoflavones. Doerge et al. [29] also
reported that total serum isoflavone levels of aglycons and
conjugates of Sprague-Dawley rats fed with soy-free diet
were ca. 16 nM while increased up to 5480 nM after orally
administered with 34 mg/kg of genistein. For humans,
Fanti et al. [4] reported that Japanese consume compara-
tively more soybean products than people from the
Western countries, serum isoflavone levels of the former
are comparatively higher than those of the latter.
Effects of dietary supplementation of SAI on lipoprotein
profilesofthetestratsareshowninTable3.Itwasnoticed
that HDL concentrations of OVX/HSAI were higher than
those of OVX group (P <0 . 0 5 ) .I nf u r t h e r ,t h eL D L
concentrations of the OVX/HSAI group were significantly
lower than those of OVX group (P < 0.05). It is generally
agreed that the higher HDL and the lower LDL concentra-
tions are of benefit in chemoprevention of cardiovascular
diseases. Some reports in the literature also indicated that
soybean isoflavones may prevent coronary heart disease
[8] and hyperlipidemia [30]. Integrated consideration of
thechangesoftotalcholesterolisalsoshowninTable3.It
is apparent that dietary supplementation of HSAI has
exhibited considerable reduction of serum cholesterol
and increase of HDL. Forsythe [31] reported that
reduction of serum cholesterol concentration by phytoes-
trogen may be achieved by increase of the metabolic rate
of LDL and VLDL. Nogowski et al. [32] demonstrated that
supplementation with 0.1% genistein for 14 days are
effective in reduction of serum cholesterol level and lipid
synthesis ofovariectomized rats andenhancementofLDL
binding to LDL receptor [33]. Reduction of serum
cholesterol and lipid biosynthesis may consequently
decrease LDL-cholesterol and increase HDL-cholesterol
contents [8,34].
Effects of SAI supplementation on liver antioxidative
activities are shown in Table 4. The HSAI supplemented
groups had higher catalase activity than those of OVX
group (P < 0.05). The trolox equivalencies were also
greater for the HSAI supplemented groups than those of
OVX group (P < 0.01). Conversely, the TBARS values were
lowerfortheSAIsupplementedgroupsthanthoseofOVX
group (P < 0.01). Iron chelating ability was greater for the
SAI supplemented groups than those of the OVX group
(P < 0.05). Other test items including GSH Px activity,
POV and CDHP contents did not differ among the test
groups (P < 0.05). Tikkanen et al. [35] reported that
genistein is able to depress hydroperoxide generation;
and increase antioxidative enzyme activities of SOD,
catalase, GSH Px and GSH reductase [36]. Bazzoli et al.
[37] reported that increase of serum total antioxidant
status (trolox equivalency) is enhanced for young women
after receiving soybean (40 g protein/d) for 4 weeks.
Kapiotis et al. [38] also reported that genistein and
daidzein may decrease cellular TBARS level. Genistein
inhibits conjugate diene hydroperoxide formation but
enhances trolox equivalency, and iron chelating and OH
-
radical scavenging activities. Soy isoflavones contain
three OH groups and offer H atoms to quench free
radicals by a chain reaction [5]. In this study, enhanced
Table 3: Effect of dietary supplementation of soy aglycons of isoflavone on serum biochemical attributes and lipoprotein profiles of
Sprague-Dawley rats
Determinations Rats with different treatments
Items Sham OVX OVX/LSAI OVX/HSAI
Estradiol (pg/ml) 65.61 ± 18.30 32.83 ± 17.88 42.18 ± 18.71 50.84 ± 25.48
Isoflavones (daidzein + genistein, μg/ml) < 0.1
b <0 . 1
b 1.28 ± 1.02
a 1.57 ± 1.20
a
Cholesterol (mg/dl) 92.75 ± 29.12
a 129.88 ± 28.11
a 108.78 ± 33.18
a 83.75 ± 21.77
b
Triacylglycerol (mg/dl) 108.12 ± 16.47 115.85 ± 12.52 109.48 ± 13.61 106.08 ± 11.83
HDL (%) 57.28 ± 10.47
ab 52.26 ± 7.14
b 53.75 ± 12.42
b 66.73 ± 10.03
a
VLDL (%) 11.11 ± 2.98 11.92 ± 2.79 11.10 ± 2.96 9.98 ± 2.61
LDL (%) 31.61 ± 8.67
ab 35.88 ± 6.14
a 35.15 ± 9.82
a 23.29 ± 8.32
b
a,bMeans (± SD, n = 10) in the same row with different superscripts differ significantly (P < 0.05). SAI: soy aglycons of isoflavone; Sham: negative
control; OVX: overiectomized rats as positive control; OVX/LSAI: overiectomized rats with low level of SAI supplementation; OVX/HSAI:
overiectomized rats with high level of SAI supplementation.
Nutrition & Metabolism 2009, 6:15 http://www.nutritionandmetabolism.com/content/6/1/15
Page 5 of 7
(page number not for citation purposes)iron chelating ability achieved by SAI supplementation
was also observed (Table 4). This was in agreement with
Lee et al. [7] who reported that soy aglycons of isoflavone
possess ferric reducing-antioxidant power. Kerry and Abbey
[6] demonstrated in an in vitro study that genistein (5–200
μmol/L) inhibits copper and peroxyl radical-mediated
LDL oxidation.
Effects of SAI supplementation on protection of the
vaginal epithelium from degeneration due to ovariect-
omy are shown in Figure 1. Normally, 4–6 layers of the
epithelial cellular linings were observed for the sham rats
(Figure 1A). In comparison, degeneration of the epithe-
lial cells and some empty vacuoles and loosen cell debris
have been noticed for the OVX rats (Figures 1B and 1C).
For rats of the SAI supplemented groups, degeneration of
the epithelial cellular linings have been less pronounced
(Figure 1D). As examined based on the rat ratios bearing
4–6 layers of epithelial cellular linings for sham, OVX,
OVX/LSAI and OVX/HSAI groups were 100, 28.6, 30.0
and 42.9%, respectively. Thus, dietary supplement of soy
isoflavones in improvement of vaginal epithelium from
degeneration due to ovariectomy-caused shortage of
estrogen is obvious. This was in agreement with
Malaivijitnond et al. [39] who reported that supplemen-
tation of genistein (0.25–2.5 mg/kg BW) induces vaginal
cornification. Kim et al. [40] also reported that vaginal
blood flow of rats decrease by ovariectomy while
increase by estradiol supplementation.
Conclusion
Health benefits evidenced by detection of higher serum
isoflavone concentrations, significantly lower serum
cholesterol and LDL contents, higher HDL contents,
increased iron chelating ability, lower liver TBARS
(thiobarbituric acid-reactive substance) contents,
enhanced liver catalase and total antioxidative (as trolox
equivalency) activities, and protection of the epithelial
cellular linings of vagina of the OVX rats have been
achievedbydietarysupplementationwithsoyaglyconsof
isoflavone. The observations that dietary SAI supplemen-
tation in performance of estrogenic effectiveness in
improvement of serum biochemical attributes, enhance-
ment of liver antioxidative capacities and protection of
vaginal epithelium are of importance from the viewpoint
of healthcare and development of dietary supplements.
Apparently, diets supplemented with soy aglycons of
isoflavone have conferred health benefits to the OVX
rats. This further supports the effectiveness that
Figure 1
Histopathological examination of the vaginal
epithelia as affected by diet supplementation with soy
aglycons of isoflavone.A :s h a mr a t s ,4 –6l a y e r so ft h e
normal epithelial cellular linings; B: OVX rats, 1–3l a y e r so f
the epithelial cellular linings; C: OVX rats, empty vacuole
(as indicated by an arrow) or loosen cell debris; and
D: OVX/HSAI rats, maintaining 4–6 layers of the epithelial
cellular linings.
Table 4: Effect of supplementation of soy aglycons of isoflavone on antioxidative capacities of rat liver extracts
Determinations Rats with different treatments
Items Sham OVX OVX/LSAI OVX/HSAI
SOD (Unit) 21.81 ± 9.44 14.84 ± 8.95 25.55 ± 11.62 18.44 ± 9.40
Catalase (Unit) 6.80 ± 1.60
b 5.46 ± 2.36
b 8.14 ± 1.59
ab 8.47 ± 0.87
a
GSH Px (Unit) 0.30 ± 0.12 0.53 ± 0.32 0.38 ± 0.35 0.54 ± 0.44
Trolox equivalent (millimole/l) 187.25 ± 46.60
ab 140.00 ± 20.51
b 181.2 ± 24.00
ab 213.14 ± 21.13
a
TBARS (nanomole MDA/ml) 82.84 ± 5.68
b 94.70 ± 1.62
a 82.76 ± 3.73
b 86.56 ± 4.92
b
Chelating iron (%) 74.60 ± 6.04
b 77.75 ± 5.62
ab 82.32 ± 2.25
a 81.01 ± 1.94
a
POV (%) 94.13 ± 1.15 94.20 ± 1.00 93.29 ± 1.47 94.30 ± 0.97
Inhibition of conjugated diene peroxide formation (%) 24.30 ± 6.10 23.88 ± 5.03 22.61 ± 6.37 22.37 ± 8.40
a,bMeans (± SD, n = 10) in the same row with different superscripts differ significantly (P < 0.05). SAI: soy aglycons of isoflavone; Sham: negative
control; OVX: overiectomized rats as positive control; OVX/LSAI: overiectomized rats with low level of SAI supplementation; OVX/HSAI:
overiectomized rats with high level of SAI supplementation; SOD: superoxide dismutase; GSH Px: glutathione peroxidase; TBARS: thiobarbituric acid-
reactive substance; POV: peroxide value.
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